Notice: Users may be experiencing issues with displaying some pages on stanfordhealthcare.org. We are working closely with our technical teams to resolve the issue as quickly as possible. Thank you for your patience.
 

Learn about the flu shot, COVID-19 vaccine, and our masking policy »

Stanford Health Care

Cells degrade a novel inhibitor of differentiation with E1A-like properties upon exiting the cell cycle MOLECULAR AND CELLULAR BIOLOGY Miyake, S., Sellers, W. R., Safran, M., Li, X. T., Zhao, W. Q., Grossman, S. R., Gan, J. M., DeCaprio, J. A., Adams, P. D., Kaelin, W. G. 2000; 20 (23): 8889-8902

Abstract

Control of proliferation and differentiation by the retinoblastoma tumor suppressor protein (pRB) and related family members depends upon their interactions with key cellular substrates. Efforts to identify such cellular targets led to the isolation of a novel protein, EID-1 (for E1A-like inhibitor of differentiation 1). Here, we show that EID-1 is a potent inhibitor of differentiation and link this activity to its ability to inhibit p300 (and the highly related molecule, CREB-binding protein, or CBP) histone acetylation activity. EID-1 is rapidly degraded by the proteasome as cells exit the cell cycle. Ubiquitination of EID-1 requires an intact C-terminal region that is also necessary for stable binding to p300 and pRB, two proteins that bind to the ubiquitin ligase MDM2. A pRB variant that can bind to EID1, but not MDM2, stabilizes EID-1 in cells. Thus, EID-1 may act at a nodal point that couples cell cycle exit to the transcriptional activation of genes required for differentiation.

View details for Web of Science ID 000168366000025

View details for PubMedID 11073989

View details for PubMedCentralID PMC86544